<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="editorial" dtd-version="1.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2025.1739229</article-id>
<article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Editorial</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Editorial: Crosstalk: skin cells and immune cells in inflammatory skin diseases, volume 2</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Yamamura</surname><given-names>Kazuhiko</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>*</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2138092/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Shiraishi</surname><given-names>Akira</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1691581/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Sato</surname><given-names>Emi</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2673895/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Williams</surname><given-names>Samuel</given-names></name>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
</contrib-group>
<aff id="aff1"><label>1</label><institution>Department of Dermatology, Kyushu University</institution>, <city>Fukuoka</city>,&#xa0;<country country="jp">Japan</country></aff>
<aff id="aff2"><label>2</label><institution>Department of Pediatrics, Kyushu University</institution>, <city>Fukuoka</city>,&#xa0;<country country="jp">Japan</country></aff>
<aff id="aff3"><label>3</label><institution>Department of Dermatology, Fukuoka University</institution>, <city>Fukuoka</city>,&#xa0;<country country="jp">Japan</country></aff>
<aff id="aff4"><label>4</label><institution>Department of Internal Medicine, University of California, San Diego</institution>, <city>San Diego</city>,&#xa0;<country country="us">United States</country></aff>
<author-notes>
<corresp id="c001"><label>*</label>Correspondence: Kazuhiko Yamamura, <email xlink:href="mailto:yamamura.kazuhiko.821@m.kyushu-u.ac.jp">yamamura.kazuhiko.821@m.kyushu-u.ac.jp</email></corresp>
</author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2025-11-19">
<day>19</day>
<month>11</month>
<year>2025</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2025</year>
</pub-date>
<volume>16</volume>
<elocation-id>1739229</elocation-id>
<history>
<date date-type="received">
<day>04</day>
<month>11</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>05</day>
<month>11</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2025 Yamamura, Shiraishi, Sato and Williams.</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Yamamura, Shiraishi, Sato and Williams</copyright-holder>
<license>
<ali:license_ref start_date="2025-11-19">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<kwd-group>
<kwd>skin</kwd>
<kwd>immune cells</kwd>
<kwd>neuron</kwd>
<kwd>inflammation</kwd>
<kwd>crosstalk</kwd>
</kwd-group>
<counts>
<fig-count count="0"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="0"/>
<page-count count="2"/>
<word-count count="524"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Systems Immunology</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes notes-type="frontiers-research-topic">
<p>Editorial on the Research Topic <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/research-topics/68319">Crosstalk: skin cells and immune cells in inflammatory skin diseases, volume 2</ext-link>
</p>
</notes>
</front>
<body>
<p>The skin, the body&#x2019;s largest organ, acts as a dynamic interface between the external environment and internal homeostasis. Beyond its well-known roles in barrier protection and sensory perception, the skin functions as an active immune organ that coordinates closely with systemic immune networks. This Research Topic, <italic>&#x201c;Crosstalk &#x2013; Skin Cells and Immune Cells in Inflammatory Skin Diseases, Volume 2,&#x201d;</italic> expands upon the first volume to further explore the multilayered relationships among epithelial, immune, and neural networks in the skin. This volume includes eight original and review articles that bridge basic discoveries and clinical implications in inflammatory dermatology.</p>
<sec id="s1">
<title>Neuro&#x2013;immune crosstalk in atopic dermatitis</title>
<p>In the field of atopic dermatitis (AD), two studies advanced our understanding of neuro&#x2013;immune interactions. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fimmu.2025.1639932">Sato et&#xa0;al.</ext-link> compared the short-term (3-month) clinical efficacy of a JAK1 inhibitor and an anti&#x2013;IL-13 antibody using real-world data. Although there was no significant difference in EASI-75 response or adverse events within this period, the JAK1 inhibitor demonstrated stronger antipruritic effects. Distinct biomarkers correlated with each treatment: eosinophil reduction in the JAK1i group and TARC reduction in the IL-13Ab group. These findings provide valuable insights for biomarker-driven personalized therapy in the era of molecularly targeted treatments. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fimmu.2025.1571120">Ishikawa et&#xa0;al.</ext-link> revealed that oncostatin M (OSM) promotes sensory nerve elongation and cutaneous hypersensitization, proposing the OSM pathway as a novel therapeutic target for chronic itch. Together, these studies deepen our understanding of the neuro-immune crosstalk that drives AD pathogenesis.</p>
</sec>
<sec id="s2">
<title>Immune dysregulation and systemic involvement in psoriasis</title>
<p>In psoriasis research, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fimmu.2025.1643418">Yao et&#xa0;al.</ext-link> provided an integrative review of the epidermal immune microenvironment (EIME), discussing its disruption from genetic, epigenetic, microbiome, and neuroimmunological perspectives. Their synthesis highlights how the IL-23/IL-17 axis sustains chronic inflammation and contributes to systemic comorbidities. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fmed.2025.1611827">&#x160;abovi&#x107; et&#xa0;al.</ext-link> demonstrated that, even during treatment, psoriasis patients may retain a procoagulant state due to impaired fibrinolysis, underscoring the link between cutaneous inflammation and systemic vascular risk. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fimmu.2025.1632426">Morino et&#xa0;al.</ext-link> reported that the SULT2B1&#x2013;cholesterol sulfate&#x2013;DOCK2 pathway plays a pivotal role in maintaining skin homeostasis by suppressing excessive immune activation. This study introduces a new epithelial&#x2013;immune regulatory axis relevant to psoriasis.</p>
</sec>
<sec id="s3">
<title>Broader perspectives on inflammatory and immune-mediated diseases</title>
<p><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fimmu.2025.1627638">Saito-Sasaki and Sawada</ext-link> reviewed the lifestyle and environmental factors that affect hidradenitis suppurativa (HS), emphasizing that diet, obesity, and sleep patterns influence immune balance and disease activity. <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fimmu.2025.1528446">He et&#xa0;al.</ext-link> identified a pathogenic IL-17-producing T-cell subset in HLA-B27-positive juvenile idiopathic arthritis (JIA). The authors linked these cells to destructive synovial inflammation and proposed that IL-17 signaling could be a potential therapeutic target. Finally, <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fimmu.2025.1592751">Uno et&#xa0;al.</ext-link> described the immunomodulatory function of hyaluronan tetrasaccharide (HA4) in the skin. HA4 suppresses inflammatory macrophage polarization while maintaining fibroblast-mediated collagen production, suggesting potential applications in skin regeneration and antifibrotic therapy.</p>
</sec>
<sec id="s4" sec-type="conclusions">
<title>Conclusion</title>
<p>Collectively, these studies redefine the skin as a &#x201c;boundary organ&#x201d; governed by multilayered crosstalk among epithelial, immune, neural, metabolic, and environmental networks. Volume 2 bridges the gap between fundamental and clinical dermatology and provides perspectives that may guide future advances in drug discovery, personalized medicine, and inflammation control.</p>
</sec>
</body>
<back>
<sec id="s5" sec-type="author-contributions">
<title>Author contributions</title>
<p>KY: Writing &#x2013; review &amp; editing, Writing &#x2013; original draft. AS: Writing &#x2013; review &amp; editing. ES: Writing &#x2013; review &amp; editing. SW: Writing &#x2013; review &amp; editing.</p></sec>
<sec id="s6" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec>
<sec id="s7" sec-type="ai-statement">
<title>Generative AI statement</title>
<p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If&#xa0;you identify any issues, please contact us.</p></sec>
<sec id="s8" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors&#xa0;and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec>
<fn-group>
<fn id="n1" fn-type="custom" custom-type="edited-by">
<p>Edited and reviewed by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/754493"> Simon Mitchell</ext-link>, Brighton and Sussex Medical School, United Kingdom</p></fn>
</fn-group>
</back>
</article>